Medicine and Dentistry
T Cell
68%
Chimeric Antigen Receptor
55%
Chimeric Antigen Receptor T-Cell
50%
Neoplasm
43%
Solid Malignant Neoplasm
43%
Integrin
34%
Krukenberg Tumor
31%
Chimeric Antigen Receptor T-Cell Immunotherapy
24%
Cancer
24%
Cancer Immunotherapy
18%
Ovarian Tumor
16%
Programmed Cell Death
15%
Adoptive Immunotherapy
15%
Alendronic Acid
15%
T Lymphocyte Receptor
15%
Mucin 1
15%
Triple Negative Breast Cancer
15%
Cancer Growth
15%
Autophagy
15%
Cell Cycle Arrest
15%
Chemoimmunotherapy
15%
Cell Cycle Checkpoint
15%
T-Cell Signaling
15%
Chimeric Antigen Receptor T-Cell Therapy
15%
Glycoprotein
15%
Ginseng Extract
15%
Chemokine Receptor CXCR2
15%
Mesothelioma
15%
Malignant Neoplasm
14%
Tumor Cell
14%
Hematologic Malignancy
12%
CD3 Antigen
11%
Antineoplastic Activity
10%
In Vitro
8%
Cell Surface
8%
Liposome
7%
Interleukin 8
7%
Clinical Trial
6%
Paclitaxel
6%
Foot and Mouth Disease Virus
6%
Immunotherapy
6%
Pleura Mesothelioma
6%
Scatter Factor
6%
Target Cell
5%
Immunosurveillance
5%
Cytokine Release
5%
Xenograft
5%
B Cell
5%
Cancer Cell
5%
Zoledronic Acid
5%
Immunology and Microbiology
T Cell
100%
Chimeric Antigen Receptor T-Cell
53%
Chimeric Antigen Receptor
47%
Integrin
45%
Adoptive Immunotherapy
31%
Antineoplastic Activity
30%
Cancer Immunotherapy
29%
CD28
22%
Interleukin 2
20%
Chimeric Antigen Receptor T-Cell Therapy
18%
Immunotherapy
18%
Cancer Cell
16%
Chemokine Receptor
15%
Ginseng Extract
15%
Glycoprotein
15%
MUC1
15%
T-Cell Signaling
15%
Programmed Cell Death
15%
Autophagy
15%
Cell Cycle Arrest
15%
Cell Cycle Checkpoint
15%
Peptides
15%
T Cell Receptor
15%
Cytokine Release
13%
Myeloid
12%
Sensitization
10%
Cytokine
10%
CD3 Antigen
8%
Xenograft
8%
B Cell
7%
Cell Surface
7%
Interleukin 8
7%
Foot and Mouth Disease Virus
6%
Tumor Cell
5%
Prostaglandin E2
5%
Prostaglandin E
5%
Co-Stimulation
5%
Caspase
5%
Tumor Volume
5%
Chemokine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
99%
Chimeric Antigen Receptor
86%
Malignant Neoplasm
53%
Solid Malignant Neoplasm
47%
Neoplasm
46%
Integrin
41%
Ovary Carcinoma
31%
Acute Myeloid Leukemia
26%
Cytokine
23%
Interleukin 2
20%
Antitumor Activity
20%
Chemotherapy
19%
Alendronic Acid
15%
Elimination
15%
Triple Negative Breast Cancer
15%
Cancer Growth
15%
Glycoprotein
15%
Chemokine Receptor CXCR2
15%
Mucin 1
15%
Ovary Tumor
15%
Clinical Trial
11%
Cytarabine
10%
Cancer Epidemiology
10%
Hematologic Malignancy
9%
Liposome
7%
Tumor Model
7%
Interleukin 8
7%
SCID Beige Mouse
5%
Paclitaxel
5%
Prostaglandin E Receptor
5%
Zoledronic Acid
5%
Prostaglandin E Receptor 2
5%
